Clinical Trial Update: RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update involving rituximab for minimal change nephrotic syndrome (MCNS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Minimal Change Nephrotic Syndrome

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Minimal Change Nephrotic Syndrome (MCNS) | Phase 2 | Status: UNKNOWN